How effective is HALAVEN® in the treatment of metastatic breast cancer (mBC)?
HALAVEN was compared with other chemotherapies or hormone
therapies commonly used to treat mBC.
In this study, 8 out of 10 women had breast cancer that had spread to other sites, including their lungs and/or liver.
Women who received HALAVEN lived, on average, 25% longer than women who received other chemotherapy or hormone therapy (13.2 months vs 10.6 months, respectively)
HALAVEN was studied in women with all types of tumor receptors. These receptors can be either positive or negative.
ER=estrogen receptor; PR=progesterone receptor; HER2/neu=human epidermal growth factor receptor 2.